10-K: Genprex Reports 2024 Financial Results, Provides Business Update

Genprex, Inc. files its 10-K, reporting a net loss for 2024 and providing updates on its clinical development programs in oncology and diabetes.

Summary

• Genprex, Inc., a clinical-stage gene therapy company, filed its 10-K report for the year ended December 31, 2024.
• The company is focused on developing gene-based therapies for cancer and diabetes.
• Genprex's oncology platform utilizes the ONCOPREX Delivery System to deliver tumor suppressor genes to cancer cells.
• REQORSA, the lead oncology drug candidate, is being developed in combination with other cancer drugs to treat NSCLC and SCLC.
• The Acclaim-1 trial, studying REQORSA with Tagrisso in NSCLC patients, is currently in the Phase 2a expansion portion, with interim analysis expected in the first half of 2026.
• The Acclaim-2 trial, studying REQORSA with Keytruda in NSCLC patients, has been discontinued due to enrollment challenges.
• The Acclaim-3 trial, studying REQORSA with Tecentriq in SCLC patients, is in the Phase 2 expansion portion, with interim analysis expected in the second half of 2025.
• In diabetes, GPX-002 is being developed for both Type 1 and Type 2 diabetes, with plans to seek further regulatory guidance from the FDA on IND-enabling studies in the second half of 2025.
• The company reported a net loss of $21.1 million for 2024, compared to a net loss of $31.0 million for 2023.
• The company expects its existing cash to fund operations into the second quarter of 2025 and will need to raise additional funds.
• The company has formed a wholly-owned subsidiary, Convergen Biotech, Inc., to focus on developing and commercializing GPX-002.

Sentiment

Score: 5

Explanation: The document presents a mixed sentiment. While there is progress in clinical trials and a decrease in net loss, the company faces significant challenges, including the need for additional funding and the discontinuation of a clinical trial. The overall outlook is uncertain.

Positives

• Advancement of REQORSA through clinical trials for NSCLC and SCLC.
• FDA Fast Track Designation for REQORSA in NSCLC and SCLC.
• FDA Orphan Drug Designation for REQORSA in SCLC.
• Development of GPX-002 for both Type 1 and Type 2 diabetes.
• Decrease in net loss from $31.0 million in 2023 to $21.1 million in 2024.
• Formation of Convergen Biotech, Inc. to focus on the diabetes program.

Negatives

• Discontinuation of the Acclaim-2 trial due to enrollment challenges.
• Recurring losses from operations and accumulated deficit.
• Need for additional funding to continue operations and clinical development.
• Uncertainty regarding the ability to obtain regulatory approval for product candidates.
• Dependence on third-party manufacturers and suppliers.
• Potential competition from other biotechnology and pharmaceutical companies.

Risks

• The company's ability to raise additional funding is uncertain.
• Clinical trials may be delayed or unsuccessful.
• Product candidates may not receive regulatory approval.
• The company faces competition from other biotechnology and pharmaceutical companies.
• The company is dependent on third-party manufacturers and suppliers.
• The company may be subject to product liability claims.
• The company may be subject to cybersecurity breaches.
• The company may be affected by health epidemics and outbreaks.

Future Outlook

The company expects its existing cash to fund operations into the second quarter of 2025 and will need to raise additional funds. The company plans to seek further regulatory guidance from the FDA on IND-enabling studies for GPX-002 in the second half of 2025. Expect to complete the enrollment of the first 19 patients for interim analysis in the Phase 2a expansion portion of the study by the end of 2025 and expect the interim analysis in the first half of 2026. Expect to complete enrollment of the first 25 patients for interim analysis in the Phase 2 expansion portion of the study in the second half of 2025.

Industry Context

The announcement reflects the ongoing challenges and high costs associated with clinical-stage gene therapy companies, particularly in the competitive fields of oncology and diabetes. The discontinuation of the Acclaim-2 trial highlights the difficulties in patient enrollment and the need for resource prioritization. The company's focus on REQORSA and GPX-002 aligns with the broader industry trend of developing targeted therapies for specific patient populations.

Comparison to Industry Standards

• Genprex's decision to discontinue the Acclaim-2 trial due to enrollment challenges is a common occurrence in the biotech industry, where competition for patients and investigators is fierce.
• The company's focus on REQORSA and GPX-002 aligns with the broader industry trend of developing targeted therapies for specific patient populations.
• The company's net loss of $21.1 million for 2024 is comparable to other clinical-stage biotech companies with no approved products.
• The company's reliance on third-party manufacturers and suppliers is a common practice in the biotech industry, but it also carries risks.
• The company's need to raise additional funding is typical for clinical-stage biotech companies, as the development of new therapies is a capital-intensive process.

Corporate Governance

Related Party Transactions

• If we are successful in commercializing REQORSA, our lead drug candidate, we will owe IRI a 1% royalty of our product sales.

Stakeholder Impact

• Shareholders: Potential dilution from future equity offerings.
• Employees: Potential impact on job security due to cost-cutting measures.
• Patients: Potential for new therapies for cancer and diabetes.
• Suppliers: Continued business relationships for manufacturing and clinical trial support.

Next Steps

• Continue enrollment and treatment of patients in the Phase 2a expansion portion of the Acclaim-1 clinical trial.
• Continue enrollment and treatment of patients in the Phase 2 expansion portion of the Acclaim-3 clinical trial.
• Seek further regulatory guidance from the FDA on IND-enabling studies for GPX-002 in the second half of 2025.
• Raise additional funds to continue operations and clinical development.

Key Dates

Keywords

REQORSA, GPX-002, NSCLC, SCLC, diabetes, gene therapy, clinical trials, ONCOPREX, TUSC2, Convergen Biotech, financial results, Genprex